We mutagenized these residues in pseudotyped HIV-1 JR.FL reporter viruses, and subjected them to single-round replication assays in the presence of 1.25–10 lgÆmL1 RC-101.. Apart from one
Trang 1heptad repeat 2 region of HIV-1 gp41
Christopher A Fuhrman1, Andrew D Warren1, Alan J Waring2, Stephen M Dutz3,
Shantanu Sharma3, Robert I Lehrer2, Amy L Cole1 and Alexander M Cole1
1 Molecular Biology & Microbiology, Biomolecular Science Center, Burnett College of Biomedical Sciences at University of Central Florida, Orlando, FL, USA
2 Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
3 Department of Chemistry and Center for Macromolecular Modeling & Materials Design, California State Polytechnic University, Pomona,
CA, USA
Defensins are effector molecules of the innate immune
system, which protect humans and other animals from
a wide range of pathogens, including bacteria, fungi
and viruses [1] There are three major defensin
families (a, b and h) They are classified based on
their b-sheet conformation, cationic charge and
unique disulfide bond pattern [2] a- and b-defensins
arose from a common pre-mammalian protein [3],
whereas h-defensins evolved directly from a-defensins
[2,4] h-defensins are formed by the fusion of two
truncated a-defensin nonapeptides by a yet to be
iden-tified mechanism, to form an octadecapeptide that
contains three intramolecular disulfide bonds, and is
macrocyclic through fusion of the N- and C-termini Fully translated and processed h-defensins were origi-nally isolated from the leukocytes of rhesus monkeys, and intact h-defensin genes exist in Old World monkeys, orangutans and a lesser ape species [4,5] Humans, gorillas, bonobos and chimpanzees retain multiple-mutated, but largely intact h-defensin genes Humans express h-defensin mRNA in a variety of cells and tissues, and their lack of h-defensin peptide expression is due to a conserved stop codon in the signal sequence that prevents translation A search of the human genome revealed five h-defensin pseudoge-nes clustered on chromosome 8 near the other a- and
Keywords
AUTODOCK ; defensin; HIV-1; innate immunity;
retrocyclin
Correspondence
A M Cole, Department of Molecular
Biology & Microbiology, Burnett School of
Biomedical Sciences, University of Central
Florida, 4000 Central Florida Boulevard,
Building 20, Room 236, Orlando, FL 32816,
USA
Fax: +1 407 823 3635
Tel: +1 407 823 3633
E-mail: acole@mail.ucf.edu
(Received 8 August 2007, revised 24
Octo-ber 2007, accepted 25 OctoOcto-ber 2007)
doi:10.1111/j.1742-4658.2007.06165.x
Retrocyclin RC-101, a h-defensin with lectin-like properties, potently inhib-its infection by many HIV-1 subtypes by binding to the heptad repeat 2 (HR2) region of glycoprotein 41 (gp41) and preventing six-helix bundle for-mation In the present study, we used in silico computational exploration
to identify residues of HR2 that interacted with RC-101, and then analyzed the HIV-1 sequence database at Los Alamos National Laboratory (New Mexico, USA) for residue variations in the heptad repeat 1 (HR1) and HR2 segments that could plausibly impart in vivo resistance Docking RC-101 to gp41 peptides in silico confirmed its strong preference for HR2 over HR1, and implicated residues crucial for its ability to bind HR2 We mutagenized these residues in pseudotyped HIV-1 JR.FL reporter viruses, and subjected them to single-round replication assays in the presence of 1.25–10 lgÆmL)1 RC-101 Apart from one mutant that was partially resis-tant to RC-101, the other pseudotyped viruses with single-site cationic mutations in HR2 manifested absent or impaired infectivity or retained wild-type susceptibility to RC-101 Overall, these data suggest that most mutations capable of rendering HIV-1 resistant to RC-101 will also exert deleterious effects on the ability of HIV-1 to initiate infections – an inter-esting and novel property for a potential topical microbicide
Abbreviations
6HB, six helix bundle; gp41, glycoprotein of 41 kDa; HR1, heptad repeat 1; HR2, heptad repeat 2.
Trang 2b-defensin genes, and one additional h-defensin gene
that had translocated to chromosome 1 [5]
Utilizing genetic information present in the
pseudo-gene, we recreated h-defensins using solid-phase
synthe-sis, and tested for antimicrobial activity [6,7] The
putative wild-type h-defensin, called retrocyclin or
RC-100, exhibited modest activity against several
Gram-positive and Gram-negative bacteria, yet
potently prevented both X4 and R5 HIV-1 replication
in CD4+ peripheral blood mononuclear cells [6] A
number of RC-100 analogues have been developed that
are effective in preventing HIV-1 infection, including
the highly active analogue RC-101 [8,9] RC-101 differs
from ‘wild-type’ retrocyclin-1 by a single
arginine-to-lysine mutation on one of the b-turns It is
nonhemolyt-ic for human red blood cells, and noncytotoxnonhemolyt-ic against
several human cell lines at concentrations up to
500 lgÆmL)1 [6,10] Importantly, RC-101 prevented
infection at low to submicromolar concentrations, and
was active against 27 clinical HIV-1 isolates from five
different clades [8,11]
Retrocyclins act prior to viral entry into host cells by
disrupting the function of glycoprotein 41 (gp41) of
HIV-1 [12,13] Retrocyclin prevented formation of the
six-helix bundle (6HB) of in vitro synthesized heptad
repeat 1 (HR1) and heptad repeat 2 (HR2) regions of
gp41 [12] During 100 days of serial passaging, HIV-1
strain BaL developed three cationic mutations in the
presence of sublethal concentrations of RC-101 [14] Of
the three mutations, one was found in gp120 and one
each in the HR1 and HR2 regions of gp41, and all
three mutations converted a polar or anionic residue to
a cationic residue [14] In addition, the cationic
muta-tion in HR2 ablated a commonly glycosylated
aspara-gine residue Loss of glycosylated residues in gp41 can
reduce the fusion ability of the virus, and alter the
shape of discontinuous epitopes [15,16], and thus the
dependence of viral replication on the presence of
RC-101 is not surprising The cationic mutations and
loss of glycosylated residues suggest an attempt by the
virus to repel the cationic lectin, RC-101 [14,17]
As all nonsynonymous mutations in
RC-101-exposed HIV-1 were cationic mutations [14], and
because HR2 is the principal target of retrocyclins [12],
we decided to study how other mutations that lead to
an increase in net positive charge in HR2 would affect
viral resistance to retrocyclins [18] Computational
analysis of gp41 revealed a region of low amino acid
diversity in the HR1-binding region of HR2 that was
favored by RC-101 in our docking model Cationic
mutations revealed only one mutation in HR2 that
offered partial resistance to RC-101; all other
muta-tions showed poor infection, did not infect, or were
inhibited by RC-101 in a manner similar to the wild-type JR.FL pseudowild-type
Results
Variability of amino acids in HR1 and HR2 corresponds to the structural role in the 6HB conformation
In order to measure the susceptibility of the envelope gene to mutation and identify viable escape mutants,
we analyzed over 900 HIV-1 group M envelope protein sequences from the HIV sequence database at Los Ala-mos National Laboratory (NM, USA) The amino acid diversity indices of HR1 and HR2 are distinctly dissimilar (Fig 1A) The majority of sites (28 of 36)
on HR1 are monomorphic and do not readily change, whereas the majority of sites (21 of 34) on HR2 are highly pliable and change readily between viral strains
Of the eight non-monomorphic sites found on HR1, six are externally exposed to the environment in the 6HB conformation
To visualize the sequence variation as a function of biochemical structure, we mapped the amino acid diversity values to the 3D model of HR2 (Fig 1B) The externally exposed regions of HR2 in the 6HB show a high amount of amino acid diversity, while the HR1-binding domain on HR2 is predominantly mono-morphic Yamaguchi-Kabata et al [20] found that dis-continuous epitopes in the a-helices of gp120 were under putative positive selection By contrast, the monomorphic sites of HR2 suggest a region under very little selection Alternatively, the regions exposed
in the 6HB conformation may be under strong puta-tive posiputa-tive selection The long-term potency of RC-101 against HIV-1 BaL could be attributed to interaction with discontinuous epitopes of the mono-morphic residues of HR2
Because all three known nonsynonymous, RC-101-evasive mutations were cationic residues [14], we chose
to measure the isoelectric points of the heptad repeat regions of all group M sequences as a marker of charge diversity The isoelectric points of the heptad repeats illustrate the ability of HIV-1 to alter its regio-nal charge in vivo While the amino acid composition
of HR2 is highly variable, its isoelectric range is acidic and significantly restricted: 96% of the isoelectric points range between 3.89 and 4.66 In contrast, HR1
is highly monomorphic but covers a wide range of iso-electric points (Fig 1C) In line with having only eight non-monomorphic sites, the isoelectric points show
a strong inclination to cluster around certain values: 8.49 (n¼ 30), 9.99 (n ¼ 52), 10.29 (n ¼ 33), 10.83
Trang 3(n¼ 569), 11 (n ¼ 140), 11.71 (n ¼ 58) and 12.01
(n¼ 12) Sequences with higher isoelectric points have
a greater number of cationic mutations with fewer
anionic residues; the converse is true for HR1
sequences with more acidic isoelectric points (data not
shown) The isoelectric range of HR1 is over twice that
of HR2, suggesting a greater in vivo variation in
elec-trostatic density
The change in free energy upon binding of
RC-101 to HR2 is consistently higher than the
energy of binding to HR1
While charge interaction plays an important role in
RC-101 viral inhibition, it is not known which residues
play an important role in binding Because RC-101
still binds gp41 in the absence of linked sugar
mole-cules, we can reasonably exclude the sugar moieties
from having a direct interaction with RC-101 [12,14]
The molecular docking program autodock [28,29]
was used to determine the affinity of RC-101 for HR1,
HR2 and the dimer (HR1 + HR2) Previous docking
procedures using the protein models of HR1 and HR2
focused on docking small molecules to the helices [36]
In contrast, RC-101 contains a large number of flexible
side chains and flexible side groups Consequently, our
docking procedures did not identify just one residue
that can be considered the principal docking site of
RC-101, but a number of RC-101 binding
conforma-tions Docking of RC-101 to HR1 alone did not result
in a strong binding energy [Fig 2] Conversely, the
minimum energy of binding to HR2 is predominantly
lower than values for small molecule inhibitors
previ-ously docked to this model [Fig 2] [36]
Anionic-to-cationic mutations on HR2 were
unable to elicit appreciable resistance to RC-101
We created HIV-1 env molecular clones to identify
mutations that alter HIV-1 susceptibility to RC-101
An expression vector containing env from JR.FL,
an R5 pseudotype, was subjected to site-directed mutagenesis to create mutant clones Because RC-101
A
B
C
Fig 1 The ‘a’ and ‘d’ heptamers of HR2 are predominantly
mono-morphic (A) The amino acid diversity index of HR1 and HR2 was
calculated for 913 group M HIV-1 viruses All amino acids for which
the index value is below the dotted line (0.05) are considered
monomorphic (B) The diversity indices were mapped to the 3D
structure of HR2 (N-terminus at the top) Monomorphic residues,
more red in color, are found in the HR1-binding region of HR2.
Highly diverse residues, more white in color, are exposed to the
external environment in the 6HB (C) Isoelectric points for HR1 and
HR2 were obtained by inputting the group M sequences into the
pI ⁄ M W tool of EXPASY The range of isoelectric points for each axis
has been restricted in order to clearly visualize the isoelectric points
of the majority of HR1 and HR2 molecules.
Trang 4viral entry inhibition is glycan-independent and charge
alteration is a common mechanism for microbial
evasion of antimicrobial peptides [12,14,37,38], we
individually mutated each negatively charged amino acid to a positively charged lysine or arginine (Fig 3A) After alteration of the env gene, the wild-type stock (nonmutated) or mutant JR.FL env clones were then used to create pseudotyped single-cycle HIV-1 luciferase reporter viruses, and RC-101 activity against each viral clone was measured Of the 10 JR.FL variants, five showed scant ability to infect HOS-CD4-CCR5 cells (Fig 3B) For all five low- or noninfectious variants, the mutation was located on the region of HR2 that is externally exposed in the 6HB conformation (heptamers b, c, e, f and g) Of the five pseudotyped variants that effectively entered HOS-CD4-CCR5 cells, only the pseudotype with a lysine at amino acid position 648 showed partial resistance to RC-101 (Fig 3C,D) Residue 648, part of the ‘g’ heptamer, is located in the central region of the helix, and, based on our modeling simulations, is a potential binding site for the positive residues on RC-101 These
Fig 3 Single-site anionic-to-cationic mutations revealed only one partially resistant variant The JR.FL env molecular clone was mutated using site-directed mutagenesis based on the HR2 sequences shown in (A) Pseudotyped viruses were then used to infect HOS-CD4-CCR5 cells (B) Pseudotypes that infected HOS cells very little or not at all in the absence of RC-101 (C) Pseudotypes that caused infection in a manner similar to the wild-type JR.FL molecular clone The percentage inhibition was calculated relative to normal infectious virus (D) All the pseudotypes were inhibited similarly to wild-type, except for E648K (P ¼ 0.05) In (A), ‘Hept.’ indicates heptamer location (‘a’–‘g’), as shown in Fig 4(C) In (B)–(D), error bars represent the SEM (n ¼ 4).
Fig 2 RC-101 forms stronger intermolecular bonds with HR2 than
with HR1 Four in silico docking experiments revealed a
signifi-cantly lower DG for RC-101 upon binding HR2 than HR1
(P ¼ 0.0005) The DG upon binding is also referred to as the final
docked energy Error bars represent the SEM.
Trang 5data suggest that the ability of the virus to form the
6HB was significantly decreased and⁄ or the mutants
lost the ability to properly form the gp41 pre-fusion
complex
RC-101 binds to the HR1-binding regions of HR2
Figure 4A shows backbone renderings of five RC-101
molecules docked to HR2, representing the five most
energetically favorable dockings in a single docking
simulation Ligands binding to HR1 were nonspecific,
as evidenced by the highly dispersed RC-101
mole-cules In contrast, RC-101 repeatedly bound to HR2
in the same region Examination of a helical represen-tation of HR2 (Fig 4B) shows that the backbone of RC-101 covers the ‘a’ and ‘d’ heptamers, and the long flexible side chains of RC-101 extend out and interact with heptamer locations ‘e’ and ‘g’ Interest-ingly, these heptamer positions are areas of low amino acid diversity (Fig 1B) that coincide with the region that binds HR1 upon 6HB formation The strong affinity of RC-101 for HR2 prevents the inter-action of HR1 and HR2, formation of the 6HB, and subsequent fusion of the host and viral membranes (Fig 4C), as supported by recent in vitro studies [12,14]
N & C Terminal
HR2
HR1
Side View
A
B
C
Fig 4 RC-101 preferentially docks to the HR1-binding domain of HR2 (A) The top five docked RC-101 molecules for a representative dock-ing, as measured by the final docked energy, are shown as gray loops near the a-helix to which they were docked The RC-101 mole-cules docked to HR1 are much more dispersed than the RC-101 molemole-cules docked to HR2 The color of each residue of HR1 and HR2 in (A) correlates with the heptamer designation shown in (B) (C) RC-101 binds to the HR1-binding region of HR2 An interaction in this region the-oretically prevents formation of the 6-helix bundle RC-101 is shown by both (D) cartoon and (E) structural representations.
Trang 6Anionic, polar and hydrophobic residues of HR2
create a preferred binding site for RC-101
The computer programs ligplot and hbplus were
used to identify specific interactions between the
ligand, RC-101 and HR2 based on proximity and
atomic angles We quantified the number of
interac-tions per HR2 residue for the lowest (best) 25% of the
docked RC-101 molecules, based on the final docked
energy for each docking experiment comprising 200
iterations of the Lamarckian genetic algorithm
(Fig 5) This allowed us to isolate regions and residues
of ligand–macromolecule interaction The applications
identified two sets of molecular interactions between
RC-101 and HR2: hydrogen bonds at residues Ser649,
Gln653 and Asn656, and hydrophobic or
nonhydro-gen-bonded contacts at residues Tyr638, Ile642 and
Leu645 (Fig 5, asterisks) Five of the six residues are
located in the ‘a’ and ‘d’ heptamer regions of HR2,
which bind HR1 upon 6HB formation The sixth
resi-due, Gln653, is located on the ‘e’ heptamer Four of
the residues are monomorphic, and the remaining two
residues have reasonably low amino acid diversity
val-ues autodock consistently bound RC-101 to a
loca-tion with low amino acid diversity that has an
important role in 6HB formation
Mutation of residues in the HR1-binding domain
of HR2 resulted in viruses that were not
replication-competent or not resistant to RC-101
Based on the above study, we created mutant
pseudo-typed JR.FL env clones that contained a cationic
muta-tion at each of the six residues observed to interact with RC-101 in silico In addition, we mutated two residues
on the 6HB-exposed portion of HR2 (heptamers ‘f’ and ‘c’) as negative controls (Fig 6A) Both of these control pseudotypes infected HOS-CD4-CCR5 cells and remained sensitive to RC-101 Four mutants were noninfectious even in the absence of RC-101 (Fig 6B) All noninfectious JR.FL mutants were located on hep-tamers that indirectly or directly interacted with HR1 [27,39] Of the JR.FL mutants that did infect HOS-CD4-CCR5 cells, none were resistant to RC-101
Discussion
The envelope protein of HIV-1 is under many kinetic restraints for proper functionality First, the short time between gp120–CD4 interaction and 6HB formation limits the time that 6HB inhibitors have to act [40,41] The strong net negative charge of HR2 and net posi-tive charge of RC-101 create a strong electrostatic attraction that probably promotes binding This is evi-dent in the marked difference observed between the nonspecific binding of RC-101 to HR1 and the specific binding to HR2 seen in this work RC-101 binds reversibly but with high affinity to glycoproteins and associates with the cellular lipids and proteins involved
in host–viral fusion [17,42] This lectin-like binding places RC-101 in the most advantageous location to affect 6HB formation
As a response to opposing host and environmental factors, HIV-1 employs a number of counter-measures, including a ‘glycan shield’ and the error-prone nature
of its reverse transcriptase Alterations in the glycan
Fig 5 RC-101 dockings prefer both the polar and hydrophobic residues on HR2 Four docking experiments were completed, each involving 200 repetitions of the Lamarckian genetic algorithm The best 25% docked RC-101 molecules (n ¼ 50) from each docking experiment were ana-lyzed for intermolecular interactions (hydro-gen bonding and hydrophobic contacts), and tabulated per HR2 residue Asterisks indi-cate the six residues of HR2 that had the greatest number of interactions with
RC-101, and which were mutated for in vitro infection assays (Fig 6) Error bars repre-sent the SEM.
Trang 7shield affect access to binding sites [43] In addition,
the 6HB formed in solution with the synthetic N36
peptide and a glycosylated C34 peptide was less
com-pact than its nonglycosylated counterpart [16] This
suggests variation in the interhelical distance, and a
possible change in the discontinuous epitopes targeted
by site-specific antibodies [44] In our analysis of
HIV-1 protein sequences, we observed many
non-monomor-phic sites with variation primarily within an amino
acid chemical grouping (e.g Ile M Leu), further
alter-ing possible bindalter-ing epitopes The question remains as
to whether HIV-1 mutations that confer partial
resis-tance against 101 change the binding site of
RC-101 or alter access to the binding site Both scenarios
are possible
In attempting to evade RC-101 inhibition, HIV-1
developed three cationic mutations, one of which
removed a glycosylated residue but caused the virus to
remain dependent on RC-101 for infectivity [14]
Anio-nic-to-cationic mutations in the HR2 region resulted in a
normal infectious mutant only 50% of the time, with all
mutants susceptible to RC-101 This suggests that the negative charge on HR2 may be important for maintain-ing the normal replication efficiency of HIV-1, possibly
by stabilizing its interaction with HR1 during 6HB for-mation Although mutations that alter the negative charge of HR2 may impair RC-101 binding, they may also have the untoward effect (for the virus) of preventing its ability to mediate the fusion process and infect cells The virus’s inability to become fully resistant to
RC-101 is further illustrated by an extension of our previ-ous work [14] Passaging the virus from days 100–140
in the presence of 10–20 lgÆmL)1 RC-101 neither induced additional mutations nor increased its resis-tance (data not shown) Collectively, our data indicate that it is unlikely that HIV-1 can mount further resis-tance to RC-101: aside from one partially resistant virus, mutant viruses either remained infectious but sensitive to RC-101, or suffered from a significant loss
of fusion efficiency
The predominant problem with current HIV-1 treat-ments is the eventual emergence of fully resistant
Fig 6 Mutation of residues in the HR1-binding region of HR2 led to noninfectious or non-RC-101-resistant mutants The JR.FL env mole-cular clone was mutated using site-directed mutagenesis based on the HR2 sequences shown in (A) Pseudotyped viruses were then used
to infect HOS-CD4-CCR5 cells Cationic mutations of RC-101-interacting residues revealed nonviable mutations (B) or normally inhibited mutant pseudotypes (C) (D) All normally infectious mutants were inhibited similarly to the wild-type In (A), ‘Hept.’ indicates heptamer location (‘a’–‘g’), as shown in Fig 4(C) In (B)–(D), error bars represent the SEM (n ¼ 4).
Trang 8mutants that are then transmitted to new hosts The
same problem is theoretically possible for widely used
topical microbicides Our work has shown that the
ability of HIV-1 to generate escape mutants against
RC-101 is limited, and thus RC-101 holds great
poten-tial as an anti-HIV-1 microbicide because it remains
effective against the virus
Experimental procedures
Computational analysis of the variation
in HR1 and HR2
Aligned envelope protein sequences of 913 unique HIV-1
group M viruses were obtained from the HIV sequence
database at the Los Alamos National Laboratory (http://
www.hiv.lanl.gov), which has been curated by Los Alamos
National Laboratory scientific staff for duplicate sequences
from the same source HIV-1 group M represents a group
of viral isolates that diverged in humans and originated
from one chimpanzee-to-human transmission event, and
is the most common group found in humans [19]
The amino acid diversity index was calculated as
Daa ¼ P20
i¼1xi
2
P20 i¼1x2
i, where x is the proportion of the ith amino acid of the 20 standard amino acids at that
location [20] The value is similar to that obtained for gene
diversity in population genetics [21] An amino acid with a
diversity index less than 0.05 is considered monomorphic
[20] The residues corresponding to HR1 and HR2 were
spliced out of the sequence file and used for evaluation in
the expasy pI⁄ Mw tool to determine the isoelectric point
[22–24]
Preparation of HR1, HR2 and retrocyclin structure
models
Three separate structural representations were required for
bio-computational experimentation: the HR1 and HR2
regions of JR.FL and the h-defensin RC-101 In the context
of computational data, the HR1⁄ HR2 nomenclature refers
only to the N36 and C34 peptides, respectively
Three-dimensional structural models of the HR1 and HR2 regions
of JR.FL were generated using the swiss-model protein
homology web server based on the HIV-1 gp41 core
struc-ture (Protein Data Bank accession number 1AIK)
pub-lished previously [25–27] The structure for RC-101 was
created using the mutagenesis function of the pymol
molec-ular graphics system, based on the structure of retrocyclin-2
(Protein Data Bank accession number 2ATG) Two in silico
mutations were performed to create RC-101: the second
arginine to a glycine and the fourth arginine to a lysine [9]
The backbone atoms for both mutated residues remained
stationary There was no need to minimize the rotational
bond energy of the mutated bonds, as all carbon–carbon or
carbon–nitrogen bonds were deemed ‘rotatable’ in the docking procedure
Computational modeling of RC-101 binding
‘Grid’ and ‘Docking’ parameter files for all RC-101 doc-kings to dimer and comparative monomer macromolecules were prepared using autodocktools (ADT) and accompa-nying scripts, and then run with autodock 3.0 and auto-grid3.0 [28,29] The grid parameters were the same for all three macromolecules The numbers of points in the x, y and z direction were 76, 76 and 126, respectively The grid spacing value was 0.4527 A˚ Finally, the grid center was defined as the x,y,z coordinate (17.449, 13.8, 5.67) All other autogridparameters remained at their default values The ligand, RC-101, was prepared using ADT according to the autodock manual [28] For each macromolecule (HR1, HR2, HR1 + HR2) and ligand (RC-101), hydrogen posi-tions were reassigned, nonpolar hydrogens were merged, and Kollman united charges were assigned to each residue The genetic algorithm variables of population size, maxi-mum number of energy evaluations and the maximaxi-mum number of generations were increased to 200, 2· 106 and
2· 105, respectively, using the methods described by Hete-nyi et al [30] as a general guideline Lower values were used because the protein model contained substantially less solvent-exposed surface area and contained less than half the average number of residues tested in previous blind-docking studies [30–32] For each blind-docking simulation, the genetic algorithm was run 200 times to return 200 possible RC-101 docked conformations autodock reports the change in free energy upon binding for each conformation
An approximate threshold range (– 9 to )11 kcalÆmol)1) separates nonspecific interactions from prominent inter-molecular bonds Each docking simulation was executed four times, and the quantitative measures of all four dock-ing simulations were averaged and the SEM calculated
Defining hydrogen and nonhydrogen bonds
Tables of hydrogen bonds and nonhydrogen bonds were generated using ligplot in conjunction with hbplus [33,34] The best 25% of the docked RC-101 molecules (n¼50), according to the final docked energy, were tabu-lated, and the mean number of bonds per residue for four independent docking executions was reported by the pro-gram, together with the SEM
Preparation of peptide
The 18-amino-acid peptide RC-101 was synthesized as pre-viously described [4,6,35] with the sequence: cyclic-GIC-RCICGKGICRCICGR After each step, the peptide was subjected to MALDI-TOF mass spectrometry to assess
Trang 9homogeneity (typically approximately 95%), and to confirm
that the observed mass agreed with the theoretical mass
Peptide concentrations were determined by quantitative
peptide analysis
Cell culture
HOS-CD4-CCR5 cells (N R Landau, Salk Institute for
Biological Studies, La Jolla, CA, USA), which allow entry
of R5 HIV-1, were acquired from the National Institutes of
Health AIDS Research and Reference Reagent Program
(Germantown, MD, USA) HOS cells were grown in
DMEM supplemented with penicillin, streptomycin, 10%
fetal bovine serum, 1 lgÆmL)1puromycin, and
mycophenol-ic acid selection medium 293T cells were grown in DMEM
with penicillin, streptomycin and 10% fetal bovine serum
HIV-1 plasmid constructs and viral entry assay
The expression vectors pNL-LucR–E–and JR.FL env were
gifts from N R Landau JR.FL is an R5 strain of HIV-1 In
total, 18 JR.FL env mutants were constructed Nine glutamic
acids on the HR2 of HIV-1 gp41 were mutated to lysines
Amino acids 632, 634, 641, 647, 648, 654, 657 and 659 were
mutated from Glu (GAA) to Lys (AAA) Amino acid 636
was mutated from Asp (GAC) to Arg (CGC) For the second
set of mutagenesis studies, polar or hydrophobic residues
were mutated to an arginine or lysine: Tyr638 (TAC) to Arg
(CGC), Ser640 (AGC) to Arg (AGG), Ile642 (ATA) to Lys
(AAA), Leu645 (CTA) to Arg (CGA), Ser649 (TCG) to
Lys (CGC), Asn651 (AAC) to Lys (AAA), Gln653 (CAA)
to Lys (AAA), and Asn656 (AAT) to Lys (AAA)
Each mutation was created from the wild-type JR.FL env
plasmid using the QuikChange multi site-directed
mutagen-esis kit (Stratagene, La Jolla, CA, USA), verified by
sequencing (University of Central Florida Biomolecular
Science Center Genomics Core Laboratory, Orlando, FL,
USA) and compared to the published JR.FL wild-type
sequence (accession number U63632) Subsequently, HIV-1
single-cycle (replication-incompetent) luciferase reporter
viruses were produced by cotransfecting 293T cells with
10 lg each of pNL-LucR–E– and one of the JR.FL env
clones Virus-containing clarified supernatants were
col-lected after 48 h by centrifugation at 1000 g for 10 min,
filtered though a 0.45 lm filter and stored at )80 C in
aliquots until needed One aliquot was used to quantify
propagated pseudovirus by p24 ELISA (Perkin Elmer,
Wal-tham, MA, USA) Another aliquot was used to ensure the
integrity of the envelope gene Viral RNA was isolated
from the JR.FL pseudotypes (viral RNA mini kit; Qiagen,
Valencia, CA, USA) A cDNA library was created from
the isolated viral RNA using the iScript Select cDNA
syn-thesis kit (Bio-Rad, Hercules, CA, USA) Then a 666 bp
envelope region containing HR1 and HR2 was
PCR-ampli-fied, and the DNA was separated using a 1.5% agarose gel
The sense primer used was 5¢-CTGTGTTCCTTGGG TTCTTGG-3¢, and the antisense primer was 5¢-CTCCACC TTCTTCTTCGATTCC-3¢ To measure the infectious abil-ity of the JR.FL pseudotypes, HOS-CD4-CCR5 cells (5· 103
per well; 96-well plate) were infected with 50 ng p24 per well of virus in the presence or the absence of RC-101 (0, 1.25, 2.5, 5 or 10 lgÆmL)1), and luciferase activity was measured 2 days later
Acknowledgements
This work was supported by grants from the National Institutes of Health: AI052017, AI065430 and AI060753 (to AMC) and AI056921 (to RIL), and from the National Science Foundation: EIA-0321333 (to SS) We thank Martin Kline (UCF) for his excellent technical help and Dr G M Morris (The Scipps Research Institute) for autodock support We are also grateful to the National Biomedical Computation Resource and Dr W Li (NBCR) for the use of their computer grid cluster SS thanks Professor
P W Mobley (California State Polytechnic University) for insightful discussions of the computational results, and CAF thanks Dr C Parkinson (UCF) for helpful discussions on molecular evolution
References
1 Selsted ME & Ouellette AJ (2005) Mammalian defensins
in the antimicrobial immune response Nat Immunol 6, 551–557
2 Lehrer RI & Ganz T (2002) Defensins of vertebrate ani-mals Curr Opin Immunol 14, 96–102
3 Liu L, Zhao C, Heng HH & Ganz T (1997) The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disul-fide topology share a common ancestry Genomics 43, 316–320
4 Tang YQ, Yuan J, Osapay G, Osapay K, Tran D, Miller CJ, Ouellette AJ & Selsted ME (1999) A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins Science
286, 498–502
5 Nguyen TX, Cole AM & Lehrer RI (2003) Evolution of primate theta-defensins: a serpentine path to a sweet tooth Peptides 24, 1647–1654
6 Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bris-tol G, Zack JA, Waring AJ, Yang OO & Lehrer RI (2002) Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1 Proc Natl Acad Sci U S A 99, 1813–1818
7 Cole AM, Wang W, Waring AJ & Lehrer RI (2004) Retrocyclins: using past as prologue Curr Protein Peptide Sci 5, 373–381
Trang 108 Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ,
Lal RB & Lehrer RI (2004) RC-101, a retrocyclin-1
ana-logue with enhanced activity against primary HIV type 1
isolates AIDS Res Hum Retroviruses 20, 1157–1165
9 Owen SM, Rudolph D, Wang W, Cole AM, Sherman
MA, Waring AJ, Lehrer RI & Lal RB (2004) A
theta-defensin composed exclusively of d-amino acids is active
against HIV-1 J Peptide Res 63, 469–476
10 Venkataraman N, Cole AL, Svoboda P, Pohl J & Cole
AM (2005) Cationic polypeptides are required for
anti-HIV-1 activity of human vaginal fluid J Immunol 175,
7560–7567
11 Wang W, Owen SM, Rudolph DL, Cole AM, Hong T,
Waring AJ, Lal RB & Lehrer RI (2004) Activity of
alpha- and theta-defensins against primary isolates of
HIV-1 J Immunol 173, 515–520
12 Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ,
Cole AM, Lu H, Yan X, Daly NL, Craik DJ, et al
(2006) Theta-defensins prevent HIV-1 Env-mediated
fusion by binding gp41 and blocking 6-helix bundle
for-mation J Biol Chem 281, 18787–18792
13 Munk C, Wei G, Yang OO, Waring AJ, Wang W,
Hong T, Lehrer RI, Landau NR & Cole AM (2003)
The theta-defensin, retrocyclin, inhibits HIV-1 entry
AIDS Res Hum Retroviruses 19, 875–881
14 Cole AL, Yang OO, Warren AD, Waring AJ,
Lehrer RI & Cole AM (2006) HIV-1 adapts to a
retrocyclin with cationic amino acid substitutions that
reduce fusion efficiency of gp41 J Immunol 176, 6900–
6905
15 Perrin C, Fenouillet E & Jones IM (1998) Role of gp41
glycosylation sites in the biological activity of human
immunodeficiency virus type 1 envelope glycoprotein
Virology 242, 338–345
16 Wang LX, Song H, Liu S, Lu H, Jiang S, Ni J & Li H
(2005) Chemoenzymatic synthesis of HIV-1 gp41
glyco-peptides: effects of glycosylation on the anti-HIV
activ-ity and alpha-helix bundle-forming abilactiv-ity of peptide
C34 Chembiochemistry 6, 1068–1074
17 Wang W, Cole AM, Hong T, Waring AJ & Lehrer RI
(2003) Retrocyclin, an antiretroviral theta-defensin, is a
lectin J Immunol 170, 4708–4716
18 Weng Y & Weiss CD (1998) Mutational analysis of
residues in the coiled-coil domain of human
immuno-deficiency virus type 1 transmembrane protein gp41
J Virol 72, 9676–9682
19 Robertson DL, Anderson JP, Bradac JA, Carr JK,
Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish
ML, Kuiken C, et al (2000) HIV-1 nomenclature
proposal Science 288, 55–56
20 Yamaguchi-Kabata Y & Gojobori T (2000)
Reevalua-tion of amino acid variability of the human
immuno-deficiency virus type 1 gp120 envelope glycoprotein and
prediction of new discontinuous epitopes J Virol 74,
4335–4350
21 Nei M (1987) Molecular Evolutionary Genetics Colum-bia University Press, New York, NY
22 Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Wil-liams KL, Appel RD & Hochstrasser DF (1999) Protein identification and analysis tools in the ExPASy server Methods Mol Biol 112, 531–552
23 Bjellqvist B, Basse B, Olsen E & Celis JE (1994) Refer-ence points for comparisons of two-dimensional maps
of proteins from different human cell types defined in a
pH scale where isoelectric points correlate with polypep-tide compositions Electrophoresis 15, 529–539
24 Bjellqvist B, Hughes GJ, Pasquali C, Paquet N, Ravier
F, Sanchez JC, Frutiger S & Hochstrasser D (1993) The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences Electrophoresis 14, 1023–1031
25 Arnold K, Bordoli L, Kopp J & Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling Bioinformat-ics 22, 195–201
26 Schwede T, Kopp J, Guex N & Peitsch MC (2003) SWISS-MODEL: an automated protein homology-mod-eling server Nucleic Acids Res 31, 3381–3385
27 Chan DC, Fass D, Berger JM & Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein Cell 89, 263–273
28 Morris GM, Goodsell DS, Halliday RS, Huey R, Hart
WE, Belew RK & Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function J Computational Chem 19, 1639–1662
29 Goodsell DS, Morris GM & Olson AJ (1996) mated docking of flexible ligands: applications of Auto-Dock J Mol Recognit 9, 1–5
30 Hetenyi C & van der Spoel D (2002) Efficient docking
of peptides to proteins without prior knowledge of the binding site Protein Sci 11, 1729–1737
31 Debnath AK, Radigan L & Jiang S (1999) Structure-based identification of small molecule antiviral com-pounds targeted to the gp41 core structure of the human immunodeficiency virus type 1 J Med Chem 42, 3203–3209
32 Kong R, Tan JJ, Ma XH, Chen WZ & Wang CX (2006) Prediction of the binding mode between
BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation Biochim Biophys Acta 1764, 766– 772
33 Wallace AC, Laskowski RA & Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams
of protein–ligand interactions Protein Eng 8, 127–134
34 McDonald IK & Thornton JM (1994) Satisfying hydro-gen bonding potential in proteins J Mol Biol 238, 777– 793
35 Leonova L, Kokryakov VN, Aleshina G, Hong T, Nguyen T, Zhao C, Waring AJ & Lehrer RI (2001)